Bio-economy is going to spearhead India’s future growth story: Dr. Jitendra Singh

Eris Lifesciences posts Q1 FY25 at Rs. 89 Cr

EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin

Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution

The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur

EMA approves Biocon Biologics’ new mAbs facility in India

Renews GMP certifications for India and Malaysia sites

Gland Pharma appoints Satnam Singh Loomba as COO

Before joining Gland, Loomba was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories.

Biocon to obtain approval for diabetes drug, Liraglutide in UK

Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus

Eris Lifesciences buys India formulation business of Biocon Biologics for Rs. 1,242 Cr

Both organisations enter into a long- term collaboration to expand patient access in India

Glenmark to launch biosimilar of anti-diabetic drug Liraglutide in India

Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs

Biocon Biologics concludes integration of acquired Biosimilars business in 120 countries

10+ emerging markets, Japan & ANZ transition in final phase

Roche to acquire Carmot Therapeutics for US$ 2.7 billion

Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases